Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) – Pipeline Review, H2 2017’, provides in depth analysis on Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Immunology, Gastrointestinal, Oncology, Central Nervous System, Dermatology, Musculoskeletal Disorders, Ophthalmology and Undisclosed under development targeting Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2)

The report reviews Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects

The report assesses Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Array BioPharma Inc

Bristol-Myers Squibb Company

Nimbus Therapeutics LLC

Pfizer Inc

Portola Pharmaceuticals Inc

Sareum Holdings Plc

Takeda Pharmaceutical Company Ltd

Theravance Biopharma Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC

2.7.10.2) - Overview

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC

2.7.10.2) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC

2.7.10.2) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC

2.7.10.2) - Companies Involved in Therapeutics Development

Array BioPharma Inc

Bristol-Myers Squibb Company

Nimbus Therapeutics LLC

Pfizer Inc

Portola Pharmaceuticals Inc

Sareum Holdings Plc

Takeda Pharmaceutical Company Ltd

Theravance Biopharma Inc

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC

2.7.10.2) - Drug Profiles

ARRY-624 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-986165 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cerdulatinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NDI-031232 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NDI-031301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NDI-031407 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OST-122 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-06700841 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAR-20347 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SART-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SART-29 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SART-33 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit TYK2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit TYK2 for Psoriasis and Uveitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit TYK2 for Ulcerative Colitis and Autoimmune Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Inhibit Tyrosine Kinase 2 for Inflammatory Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TD-1473 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TD-3504 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC

2.7.10.2) - Dormant Products

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC

2.7.10.2) - Discontinued Products

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC

2.7.10.2) - Product Development Milestones

Featured News & Press Releases

Aug 08, 2017: Theravance Biopharma Reports Encouraging Data from First Cohort of Patients in Phase 1b Clinical Trial of TD-1473 in Ulcerative Colitis

Jun 23, 2017: European Hematology Association: Two is better than one: The Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Rapid Tumor Responses in a Phase 2 Study for Relapsed/Refractory NHL

Jun 15, 2017: Portola Pharmaceuticals Presents Interim Phase 2a Safety and Efficacy Data for Cerdulatinib at the International Congress of Malignant Lymphoma

Jun 14, 2017: Bristol-Myers Squibb To Present on BMS-986165 at the Annual European Congress of Rheumatology (EULAR 2017)

May 18, 2017: Portola Pharmaceuticals Announces Phase 2a Safety and Efficacy Cerdulatinib Data to be Presented at the European Hematology Association

May 09, 2017: Portola Pharmaceuticals Announces Cerdulatinib Data to be Presented at the International Conference on Malignant Lymphoma

Feb 17, 2017: Theravance Biopharma Presents Positive Clinical Data on TD-1473 at the 12th Congress of the European Crohn's and Colitis Organization

Feb 13, 2017: Theravance Biopharma to Present Clinical Data on TD-1473 at the 12th Congress of the European Crohn's and Colitis Organization

Nov 29, 2016: Sareum to Present TYK2 Cancer Research Programme at the 2016 AACR-NCI-EORTC International Conference

Nov 28, 2016: Portola Pharmaceuticals Announces Cerdulatinib Data to be Presented at 2016 American Society of Hematology Annual Meeting and Exposition

Oct 24, 2016: Sareum Holdings: Successful Outcome from TYK2 Feasibility Study

Oct 04, 2016: Theravance Biopharma Announces First Subject Dosed in Phase 1b Clinical Trial of TD-1473 in Patients With Moderate to Severe Ulcerative Colitis

Jun 09, 2016: Theravance Biopharma Reports Positive Results From Phase 1 Clinical Trial of TD-1473, a GI-Targeted Pan-Janus Kinase (JAK) Inhibitor

Jun 01, 2016: Portola Pharmaceuticals Announces Dosing of First Patient in Phase 2a Study of Cerdulatinib for Treatment of Hematologic Cancer and Upcoming Presentations of New Phase 1 Clinical Data at ASCO and EHA Annual Meetings

Apr 14, 2016: Portola Pharmaceuticals Announces Upcoming Cerdulatinib Data Presentation at American Association for Cancer Research (AACR) Annual Meeting 2016

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indications, H2 2017

Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Investigation by Universities/Institutes, H2 2017

Products under Investigation by Universities/Institutes, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pipeline by Array BioPharma Inc, H2 2017

Pipeline by Bristol-Myers Squibb Company, H2 2017

Pipeline by Nimbus Therapeutics LLC, H2 2017

Pipeline by Pfizer Inc, H2 2017

Pipeline by Portola Pharmaceuticals Inc, H2 2017

Pipeline by Sareum Holdings Plc, H2 2017

Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017

Pipeline by Theravance Biopharma Inc, H2 2017

Dormant Projects, H2 2017

Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Top 10 Indications, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports

Analytics by GoSquared